RUNX1 cooperates with FLT3-ITD to induce leukemia

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Acute Myeloid Leukemia (AML) pathogenesis involves gene deregulation affecting cell growth and differentiation.
• FLT3-Internal Tandem Duplications (ITDs) are common in AML, associated with poor prognosis and increased myeloproliferation.
• RUNX1, a transcription factor, is highly expressed in FLT3-ITD AML despite its known tumor-suppressor role, presenting a paradox.

Purpose of the Study:

• To investigate the cooperative role of RUNX1 and FLT3-ITD in AML development.
• To elucidate the functional impact of RUNX1 activity in the context of FLT3-ITD mutations.
• To identify downstream targets and mechanisms through which RUNX1 and FLT3-ITD cooperate in leukemogenesis.

Main Methods:

• Coexpression analysis of RUNX1 and FLT3-ITD in AML patient samples.
• Functional studies to assess the impact of RUNX1 activity on cell proliferation and differentiation.
• Identification and validation of direct gene targets of RUNX1 and FLT3-ITD signaling.

Main Results:

• FLT3-ITD directly modulates RUNX1 activity, leading to its upregulation and phosphorylation.
• Cooperative action of activated RUNX1 and FLT3-ITD drives AML.
• Inactivation of RUNX1 in AML tumors releases differentiation block and reduces ribosome biogenesis gene expression.
• HHEX is identified as a direct target of RUNX1 and FLT3-ITD, and its expression is elevated in FLT3-ITD AML.
• HHEX can substitute for RUNX1 in cooperating with FLT3-ITD to induce AML.

Conclusions:

• RUNX1 exhibits an unexpected oncogenic function in AML when cooperating with FLT3-ITD.
• The study elucidates a novel mechanism of leukemogenesis involving RUNX1 and FLT3-ITD.
• Targeting RUNX1 activity presents a potential therapeutic strategy to enhance FLT3 inhibitor efficacy in AML treatment.